drugset / Trial / NCT00811486
Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure
Withdrawn
University of Colorado, Denver
RandomizedParallel-groupOpen-labelTreatment
Summary
Secondary hyperaldosteronism and the non-osmotic release of arginine vasopressin (AVP) are the major factors in sodium and water retention in pulmonary arterial hypertension with right ventricular failure. Natriuretic doses of mineralocorticoid antagonist and aquaretic doses of V2 receptor antagonist will attenuate the sodium and water retention respectively, and be associated with clinical improvement.
Timeline
- Start
- 2009-01
- Primary completion
- 2010-07
- Completion
- 2010-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Conivaptan | Small molecule | 20 mg | Intravenous |
| Subject | Spironolactone | Small molecule | 50 mg | Oral |
| Subject | Spironolactone | Small molecule | 200 mg | Oral |